Class 2 recall-Levothyroxine 12.5mcg tablets Teva

Reason: “Teva UK Limited is recalling the above batch of Levothyroxine 12.5mcg Tablets in response to a lower than required assay result discovered during routine stability testing.”

MHRA drug alert date  02 March 2023

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-teva-uk-limited-levothyroxine-12-dot-5mcg-tablets-el-23-a-slash-06?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=16a65f83-bc8f-4111-ab4d-5bbfef5ce896&utm_content=immediately

MHRA ref: MDR 226-02/23

Further Information

For any Levothyroxine stock enquiries please contact the Teva UK Limited Customer Solutions team on 0800 590 502.

For more information or medical enquiries, please contact Teva UK Limited by phone on 020 7540 7117 or by email to medinfo@tevauk.com

To report an adverse drug event to Teva UK Limited, please call 020 7540 7337, email uk.safety@tevauk.com or complete the online form at www.tevauk.com/Reporting-side-effects.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 Caution in use- Zestoretic 20/12.5mg tablets

Atnahs Pharma UK has informed the MHRA that the Patient Information Leaflet (PIL) packaged in certain batches of Zestoretic 20mg/12.5mg Tablets contains outdated safety information

MHRA drug alert date: 27th February 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-atnahs-pharma-uk-zestoretic-20mg-slash-12-dot-5mg-tablets-el-23-a-slash-05

This is a caution in use only we are not accepting stock returns.

Further Information

For more information, medical information queries, replacement PIL enquiries and stock control queries, please contact: info@pharmanovia.com

Class 4 Caution in use- Lemsip Max cold and flu capsules

Reckitt Benckiser Healthcare (UK) Limited has informed the MHRA that a typographical error has been identified on the end flap of the outer carton of some batches of Lemsip Max Cold & Flu Capsules.

MHRA drug alert date: 23^rd February 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-reckitt-benckiser-healthcare-uk-limited-lemsip-max-cold-and-flu-capsules-el-23-a-slash-04?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=c26db05c-8d64-472f-a107-53c53ded316e&utm_content=immediately

This is a caution in use only we are not accepting stock returns.

Further Information

For medical information and stock control queries please contact: ConsumerHealth_GB@Reckitt.com and / or 03332005345.

STOP DISTRIBUTION-EYECEE ONE PRELOADED & EYECEE ONE CRYSTAL PRELOADED INTRAOCULAR LENSES - ALLIANCE DO NOT STOCK

The MHRA is aware of reports of increased intraocular pressure in patients recently implanted with EyeCee One preloaded and EyeCee One Crystal preloaded intraocular lenses (IOLs).

MHRA drug alert date  26 January 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/eyecee-one-preloaded-and-eyecee-one-crystal-preloaded-intraocular-lenses-iols-stop-using-immediately-and-quarantine-all-preloaded-eyecee-one-lenses-dsi-slash-2023-slash-001?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e1e64c23-db14-4853-b96f-0ce8770935db&utm_content=immediately

Alliance do not stock this product and therefore we are not accepting stock returns.

Advice for patients

The advice in this notice is aimed at the healthcare teams who are responsible for providing and monitoring lenses used in cataract surgery. The MHRA is urgently investigating this issue and will be advising healthcare professionals on next steps, including the need to contact patients who may be affected, as soon as more information is available. If you are affected, your healthcare professional will contact you in due course. If you or somebody in your care had cataract surgery recently and are concerned, please contact the hospital where you had surgery for advice.

CLASS 3 RECALL- LACIDIPINE 4MG TABLETS

Dr Reddy’s Laboratories (UK) Limited is recalling two batches of Lacidipine 4 mg Film-Coated Tablets as a precautionary measure due to the presence of an unknown solvent-like odour.

MHRA drug alert date: 18th January 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-dr-reddys-laboratories-uk-ltd-lacidipine-4-mg-film-coated-tablets-el-23-a-slash-03?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2e503df5-1891-40b4-a054-1dd7fb232117&utm_content=immediately

Further Information

For medical information enquiries please contact Dr. Reddy’s Laboratories (UK) Ltd Medical Information Department at 01748 828873, or email drreddysGB@EU.ProPharmaGroup.com.

For stock control enquiries please contact Dr. Reddy’s Laboratories (UK) Ltd Customer Services Team at 01482 389858 (or main switchboard at 01482 860228), or email customerserviceuk@drreddys.com.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

CLASS 2 RECALL - DIOCTYL CAPSULES 100MG (100 PACK)

Reason: “UCB Pharma Ltd is recalling the above batch of product as a precautionary measure due to the presence of a foreign capsule being found in a sealed pack. The Marketing Authorisation Holder’s investigation concluded that this was the result of a product mix up during the manufacturing process.

MHRA drug alert date  18 January 2023

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ucb-pharma-ltd-dioctyl-100-mg-capsules-el-23-a-slash-02?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=5f2c6167-607e-4cbf-b15b-d3345054e3dc&utm_content=immediately

Further Information

For more information, medical or supply enquiries, please contact UCB Pharma Ltd on (+44) 01753 777100 or 0800 279 3177 (freephone) or by email at UCBCares.UK@ucb.com.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

CLASS 4 CAUTION IN USE - BYLVAY 1200 MICROGRAMS HARD CAPSULES

Class 4 Drug Caution In Use - Bylvay 1200 Micrograms Hard Capsules

Albireo AB has informed the MHRA that there is a typographical error with the text on the side panel of the bottle label for a specific batch of Bylvay 1200 micrograms Hard Capsules.

MHRA drug alert date: 3^rd January 2023

MHRA drug alert link:

https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-albireo-ab-bylvay-1200-micrograms-hard-capsules-el-23-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=c026b52c-0482-46b8-aeef-c360417c08cf&utm_content=immediately 

This is a caution in use only we are not accepting stock returns.

Further Information

For medical information and stock control queries please contact: medinfo@Albireopharma.com

Class 4 Medicines Defect Information: Galderma (U.K.) Limited, Etrivex 500 micrograms/g Shampoo

Galderma (U.K.) Limited has informed the MHRA that the patient information leaflet (PIL) packaged in specific batches of Etrivex Shampoo is missing safety information

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-galderma-uk-limited-etrivex-500-micrograms-slash-g-shampoo-el-22-a-slash-51?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=90e00faf-8782-4c58-b00a-5c6c196d3cb8&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For more information, medical information queries or replacement PIL enquiries, please contact: medinfo.uk@galderma.com

For stock control queries, please contact: sales.uk@galderma.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Class 4 Medicines Defect Information: ADVANZ Pharma Ltd, MacroBID 100mg Prolonged-Release Capsules

ADVANZ PHARMA has made the MHRA aware that certain batches of MacroBID 100mg Prolonged-Release Capsules have been packed with the incorrect Patient Information Leaflet (PIL).

MHRA drug alert date: 5th December 2022

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-advanz-pharma-macrobid-100mg-prolonged-release-capsules-el-22-a-slash-50?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=7dca1a8e-a797-4234-b6cb-7c92576fc0d0&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For further information, medical enquiries, stock information or request for printed copy of the associated SmPC, please contact telephone: + 44 (0) 208 5889 131 or via email: medicalinformation@advanzpharma.com.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Class 4 Medicines Defect Information: Lucis Pharma Ltd, Oxycodone Hydrochloride 10mg/ml oral solution

Lucis Pharma Ltd has informed the MHRA that there is a typographical error with text on the rear side of the outer packaging for Oxycodone Hydrochloride 10mg/ml Oral Solution.

MHRA drug alert date: 29 November 2022

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-lucis-pharma-ltd-oxycodone-hydrochloride-10mg-slash-ml-oral-solution-el-22-a-slash-49?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1864253f-7b0a-4b30-9aad-78ec2edb6c19&utm_content=immediately

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further information

For medical information and stock control queries please contact: enquiries@lucispharma.co.uk.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.